The authors found that THP1 (NRAS mutated—KMT2A rearranged) showed greater sensitivity to MEK inhibitors than HL60 and OCI-AML3 (NRAS mutated—non-KMT2A rearranged) and RAS wild-type non-KMT2A-rearranged AML cell lines. The gene discussed is MAP2K7; the disease is acute myeloid leukemia.